** Shares of drugmaker Vertex Pharmaceuticals VRTX.O fall 1.8% to $461 in morning trade
** Co on Monday reported Q4 profit of $3.98/shr, missing analysts' est. of $4.03/shr - as per LSEG data
** Q4 sales of co and partner CRISPR's CRSP.BN sickle-cell disease therapy, Casgevy, came in at $8 mln vs est. of $17.7 mln
** Brokerage TD Cowen says sales of Casgevy could be hurt by adoption and manufacturing-related challenges; does not expect VRTX to post billion-dollar revenues for the therapy
** VRTX forecast 2025 rev. of $11.75 bln to $12.0 bln, vs. est. of $11.84 bln
** Co said it aims to launch five new treatments by 2028, which includes a next-generation cystic fibrosis drug and its recently approved non-opioid painkiller, Journavx
** Stock has risen 11% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.